Halozyme Therapeutics (HALO) Gross Profit (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Gross Profit data on file, last reported at $297.5 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 37.43% year-over-year to $297.5 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 38.02% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 36.44% from the prior year.
• Gross Profit for Q1 2026 stood at $297.5 million, down from $373.0 million in the prior quarter.
• Over the last five years, Gross Profit for HALO reached as high as $373.0 million in Q4 2025 and fell as low as $101.4 million in Q1 2022.
• Historically, Gross Profit has averaged $204.6 million across 5 years, with a median of $177.7 million in 2023.
• Across the five-year window, Gross Profit surged 73.32% in 2022 and declined 0.28% in 2023, its largest moves.
• Year by year, Gross Profit stood at $139.4 million in 2022, then climbed by 27.53% to $177.7 million in 2023, then soared by 44.0% to $256.0 million in 2024, then jumped by 45.73% to $373.0 million in 2025, then slipped by 20.25% to $297.5 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $297.5 million in Q1 2026, $373.0 million in Q4 2025, and $299.0 million in Q3 2025.